Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Westlake Therapeutics (Hangzhou) Co. Limited currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner and is situated within 1 distinct art unit. The concentration of 1 pending office action under 1 distinct examiner simplifies the monitoring process for the applicant. The use of 1 distinct art unit indicates a specific technical niche within the broader pharmaceutical category.
STEADMAN, DAVID J is the busiest examiner, managing 1 busiest examiner pending action. Since STEADMAN, DAVID J is the only examiner currently reviewing the company's pending work, his specific history with biotechnology patents will be the primary factor in the immediate prosecution timeline. Practitioners should prepare for the 1 pending office action by researching the examiner's typical rejection types and responsiveness to interviews. The fact that 1 distinct examiner is involved suggests a straightforward prosecution path without the need for cross-unit coordination.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEADMAN, DAVID J | 1 | 57.7% | +29.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906435 | Modified Red Blood Cells and Uses Thereof for Delivering Agents | STEADMAN, DAVID J | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17906435 | Modified Red Blood Cells and Uses Thereof for Delivering Agents | STEADMAN, DAVID J | 1656 | §103§112DP | Non-Final OA | — | Pending | Sep 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial